Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

被引：0
|
作者：
Cobain, Erin F. [1 ]
Hayes, Daniel F. [1 ]
机构：
[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 32期
关键词：
PATIENT-LEVEL METAANALYSIS; RIBOCICLIB PLUS FULVESTRANT; CELL-FREE DNA; POSTMENOPAUSAL WOMEN; MUTATIONS; LETROZOLE; SURVIVAL; TRIAL; MULTICENTER; PALBOCICLIB;
D O I：
10.1200/JCO.22.00702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3673 / +
页数：5
相关论文
共 50 条
  • [1] Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors
    Groheux, David
    Hatt, Mathieu
    Hindie, Elif
    Giacchetti, Sylvie
    de Cremoux, Patricia
    Lehmann-Che, Jacqueline
    Martineau, Antoine
    Marty, Michel
    Cuvier, Caroline
    Cheze-Le Rest, Catherine
    de Roquancourt, Anne
    Visvikis, Dimitris
    Espie, Marc
    CANCER, 2013, 119 (11) : 1960 - 1968
  • [2] Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer
    Masuda, Norikazu
    Sato, Nobuaki
    Morimoto, Takashi
    Ueno, Takayuki
    Kanbayashi, Chizuko
    Kaneko, Koji
    Yasojima, Hiroyuki
    Saji, Shigehira
    Sasano, Hironobu
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer
    Rios-Hoyo, Alejandro
    Cobain, Erin
    Huppert, Laura A.
    Beitsch, Peter D.
    Buchholz, Thomas A.
    Esserman, Laura
    van't Veer, Laura J.
    Rugo, Hope S.
    Pusztai, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22)
  • [4] Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer
    Gogineni, Keerthi
    Kalinsky, Kevin
    JCO ONCOLOGY PRACTICE, 2022, 18 (04) : 247 - +
  • [5] Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
    Royce, Melanie
    Bachelot, Thomas
    Villanueva, Cristian
    Ozguroglu, Mustafa
    Azevedo, Sergio J.
    Cruz, Felipe Melo
    Debled, Marc
    Hegg, Roberto
    Toyama, Tatsuya
    Falkson, Carla
    Jeong, Joon
    Srimuninnimit, Vichien
    Gradishar, William J.
    Arce, Christina
    Ridolfi, Antonia
    Lin, Chinjune
    Cardoso, Fatima
    JAMA ONCOLOGY, 2018, 4 (07) : 977 - 984
  • [6] Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Shen, Le-Sang
    Jin, Xiao-Yan
    Wang, Xu-Meng
    Tou, Lai-Zhen
    Huang, Jian
    CHINESE MEDICAL JOURNAL, 2020, 133 (09) : 1099 - 1108
  • [7] Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Khanzada, Mikail
    Zaheer, Zaofashan
    Fatima, Eeshal
    Bakhtiar, Muhammad
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [8] Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
    Bachelot, Thomas
    Cottu, Paul
    Chabaud, Sylvie
    Dalenc, Florence
    Allouache, Djelila
    Delaloge, Suzette
    Jacquin, Jean-Philippe
    Grenier, Julien
    Bouvet, Laurence Venat
    Jegannathen, Apurna
    Campone, Mario
    Del Piano, Francesco
    Debled, Marc
    Hardy-Bessard, Anne-Claire
    Giacchetti, Sylvie
    Mouret-Reynier, Marie-Ange
    Barthelemy, Philippe
    Kaluzinski, Laure
    Mailliez, Audrey
    Legouffe, Eric
    Sephton, Matthew
    Bliss, Judith
    Canon, Jean-Luc
    Penault-Llorca, Frederique
    Lemonnier, Jerome
    Cameron, David
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3699 - +
  • [9] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
    Rizki, Hirah
    Hillyar, Christopher
    Abbassi, Omar
    Miles-Dua, Sascha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
  • [10] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Burris, Howard A., III
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
12345